Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Switzerland Pharmaceuticals and Healthcare Report Q2 2008

Published by: Business Monitor International

Published: Apr. 22, 2008 - 70 Pages


Table of Contents


Executive Summary
Switzerland Pharmaceuticals And Healthcare Industry SWOT
Switzerland Political SWOT
Switzerland Economic SWOT
Pharmaceutical Business Environment Ratings
Table: Western Europe Pharmaceutical Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Switzerland - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Table: A Comparison Of Medicine Prices In Western
Industry Developments
Healthcare Sector
Pharmaceutical Sector
Domestic Industry
Multinational Sector
Roche Boosted By Biotechnology
Novartis Announces Restructuring
Research And Development Sector
Hospital Sector
Biotechnology Sector
Industry Forecast Sce34
Overall Market Forecast
Table: Swiss Pharmaceutical Expenditure Indicators, 2006-2012
Key Growth Factors - Industry
Table: Swiss Health Expenditure Indicators, 2006-2012
Key Growth Factors - Macroeconomic
Table: Switzerland - Economic Forecasts
Branded Forecasts
Table: Swiss Patented Pharmaceutical Market Indicators, 2005-2012
OTC Market Forecast
Table: Swiss OTC Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Generics Market Forecasts
Table: Swiss Generics And Branded Market Indicators, 2006-2012
Export/Import Forecasts
Table: Swiss Pharmaceuticals Exports And Imports Indicators, 2006-2012 (US$mn)
Medical Devices
Table: Switzerland Medical Device Market Indicators, 2006-2012 (US$bn unless otherwise stated)
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Sanofi-Aventis
Merck & Co
Indigenous Manufacturers
Novartis
Roche
Serono (Merck-Serono)
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Abstract

Switzerland’s drug market is displaying strong growth and should reach a value of US$5.56bn by 2012,
driven by demand for innovative pharmaceuticals. Much of the recent growth has been as a result of
drugs that have been on the market for less than two years. This reflects the advanced nature of
Switzerland’s drug market and bodes well for future expansion.


Switzerland’s leading pharmaceutical firms Novartis and Roche produced mixed results in 2007,
reflecting the current uncertain nature of the global pharmaceutical market. Novartis’s total sales reached
US$39.8bn, with net income jumping by 66% to US$11.97bn. Yet in the pharmaceuticals division, which
is the firm’s most important business, operating income fell to US$6.08bn, from US$6.7bn in 2006, due
primarily to a poor performance in the US. Roche posted strong results, with sales reaching CHF46.13bn
(US$46.26bn), an increase of 10%. Much of this top line growth was as a result of a strong performance
in its pharmaceuticals business, where sales grew by 11% to CHF36.8bn (US$36.9bn).


BMI has included Switzerland’s medical devices market in its forecasts for the first time. This sector is
highly developed and was worth approximately US$1.2bn in 2007. By 2012, the market should reach a
value of US$1.5bn, representing a compound annual growth rate (CAGR) of around 5%, which is roughly
in line with growth in the pharmaceutical market. Like Switzerland’s drug sector, the medical devices
industry is characterised by impressive technological standards and a high density of operators.


Switzerland retains its position in BMI’s Business Environment Ranking for the Western Europe region
and remains in second place in global terms. The country’s regulatory structures are superb, while percapita
drug expenditure is high. The country’s strong economy and stable political environment is highly
beneficial.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options

Search Inside Report


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008